AnaptysBio (NASDAQ:ANAB) Shares Gap Up – What’s Next?

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $17.08, but opened at $18.01. AnaptysBio shares last traded at $19.49, with a volume of 220,227 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ANAB. Wolfe Research started coverage on AnaptysBio in a report on Tuesday, February 4th. They set an “outperform” rating and a $25.00 price target on the stock. Wedbush reissued an “outperform” rating and set a $40.00 target price on shares of AnaptysBio in a research report on Wednesday, February 12th. Wells Fargo & Company increased their target price on shares of AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Monday, March 3rd. Finally, Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $35.11.

AnaptysBio Stock Performance

The business has a fifty day moving average of $16.80 and a 200-day moving average of $22.47. The company has a market capitalization of $581.42 million, a P/E ratio of -3.12 and a beta of 0.02.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.89. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The business had revenue of $43.11 million for the quarter, compared to analysts’ expectations of $10.17 million. Sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In related news, Director Ecor1 Capital, Llc acquired 6,646 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were acquired at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 33.70% of the company’s stock.

Institutional Investors Weigh In On AnaptysBio

Several large investors have recently made changes to their positions in the business. FMR LLC increased its position in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Frazier Life Sciences Management L.P. increased its position in shares of AnaptysBio by 2.0% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after purchasing an additional 43,598 shares during the last quarter. Vanguard Group Inc. increased its position in shares of AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company’s stock valued at $24,411,000 after purchasing an additional 143,584 shares during the last quarter. Fairmount Funds Management LLC purchased a new stake in shares of AnaptysBio during the 4th quarter valued at $24,050,000. Finally, Boxer Capital Management LLC purchased a new stake in shares of AnaptysBio during the 4th quarter valued at $17,212,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.